Novartis antifungals
This article was originally published in The Tan Sheet
Executive Summary
Soltec Research grants exclusive global license for Liquipatch topical drug delivery technology to Novartis for all antifungal applications, Soltec parent Connetics announces April 8. Novartis previously licensed the technology only for use in its Lamisil line. In addition to paying Soltec an undisclosed sum to expand the license, Novartis will continue to pay product development costs, licensing fees, sales royalties and milestone payments. Liquipatch applies to skin "like a conventional topical gel and dries to form a thin, invisible, water-resistant film," Connetics says...